These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30737480)

  • 41. Alkaptonuria: Current Perspectives.
    Zatkova A; Ranganath L; Kadasi L
    Appl Clin Genet; 2020; 13():37-47. PubMed ID: 32158253
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HGDiscovery: An online tool providing functional and phenotypic information on novel variants of homogentisate 1,2- dioxigenase.
    Karmakar M; Cicaloni V; Rodrigues CHM; Spiga O; Santucci A; Ascher DB
    Curr Res Struct Biol; 2022; 4():271-277. PubMed ID: 36118553
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alkaptonuria: a very rare metabolic disorder.
    Aquaron R
    Indian J Biochem Biophys; 2013 Oct; 50(5):339-44. PubMed ID: 24772955
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of tyrosine pathway enzymes in mice demonstrates that homogentisate 1,2-dioxygenase deficiency in the liver is responsible for homogentisic acid-derived ochronotic pigmentation.
    Wilson PJM; Ranganath LR; Bou-Gharios G; Gallagher JA; Hughes JH
    JIMD Rep; 2021 Mar; 58(1):52-60. PubMed ID: 33728247
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
    Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
    Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ochronotic rheumatism in Algeria: clinical, radiological, biological and molecular studies--a case study of 14 patients in 11 families.
    Ladjouze-Rezig A; Rodriguez de Cordoba S; Aquaron R
    Joint Bone Spine; 2006 May; 73(3):284-92. PubMed ID: 16085442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. R58fs mutation in the HGD gene in a family with alkaptonuria in the UAE.
    Abdulrazzaq YM; Ibrahim A; Al-Khayat AI; Nagelkerke N; Ali BR
    Ann Hum Genet; 2009 Jan; 73(1):125-30. PubMed ID: 18945288
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of para-Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria.
    Laschi M; Bernardini G; Dreassi E; Millucci L; Geminiani M; Braconi D; Marzocchi B; Botta M; Manetti F; Santucci A
    ChemMedChem; 2016 Apr; 11(7):674-8. PubMed ID: 26947423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutation and polymorphism analysis of the human homogentisate 1, 2-dioxygenase gene in alkaptonuria patients.
    Beltrán-Valero de Bernabé D; Granadino B; Chiarelli I; Porfirio B; Mayatepek E; Aquaron R; Moore MM; Festen JJ; Sanmartí R; Peñalva MA; de Córdoba SR
    Am J Hum Genet; 1998 Apr; 62(4):776-84. PubMed ID: 9529363
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Homogentisic acid induces aggregation and fibrillation of amyloidogenic proteins.
    Braconi D; Millucci L; Bernini A; Spiga O; Lupetti P; Marzocchi B; Niccolai N; Bernardini G; Santucci A
    Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):135-146. PubMed ID: 27865997
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model.
    Tinti L; Spreafico A; Braconi D; Millucci L; Bernardini G; Chellini F; Cavallo G; Selvi E; Galeazzi M; Marcolongo R; Gallagher JA; Santucci A
    J Cell Physiol; 2010 Oct; 225(1):84-91. PubMed ID: 20648626
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Natural history of alkaptonuria revisited: analyses based on scoring systems.
    Ranganath LR; Cox TF
    J Inherit Metab Dis; 2011 Dec; 34(6):1141-51. PubMed ID: 21748407
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice.
    Keenan CM; Preston AJ; Sutherland H; Wilson PJ; Psarelli EE; Cox TF; Ranganath LR; Jarvis JC; Gallagher JA
    JIMD Rep; 2015; 24():45-50. PubMed ID: 25940034
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alkaptonuria is a novel human secondary amyloidogenic disease.
    Millucci L; Spreafico A; Tinti L; Braconi D; Ghezzi L; Paccagnini E; Bernardini G; Amato L; Laschi M; Selvi E; Galeazzi M; Mannoni A; Benucci M; Lupetti P; Chellini F; Orlandini M; Santucci A
    Biochim Biophys Acta; 2012 Nov; 1822(11):1682-91. PubMed ID: 22850426
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A quantitative assessment of alkaptonuria: testing the reliability of two disease severity scoring systems.
    Cox TF; Ranganath L
    J Inherit Metab Dis; 2011 Dec; 34(6):1153-62. PubMed ID: 21744089
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oxidative stress and mechanisms of ochronosis in alkaptonuria.
    Braconi D; Millucci L; Bernardini G; Santucci A
    Free Radic Biol Med; 2015 Nov; 88(Pt A):70-80. PubMed ID: 25733348
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
    Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
    J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Redox proteomics gives insights into the role of oxidative stress in alkaptonuria.
    Braconi D; Millucci L; Ghezzi L; Santucci A
    Expert Rev Proteomics; 2013 Dec; 10(6):521-35. PubMed ID: 24206226
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of an Effective Therapy for Alkaptonuria - Lessons for Osteoarthritis.
    Gallagher JA; Dillon JP; Ranganath LR
    Rheumatol Immunol Res; 2021 Jun; 2(2):79-85. PubMed ID: 36465977
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular diagnosis of alkaptonuria mutation by analysis of homogentisate 1,2 dioxygenase mRNA from urine and blood.
    Ramos SM; Hernández M; Roces A; Larruga JM; González P; González AM; Pinto FM; Cabrera VM
    Am J Med Genet; 1998 Jun; 78(2):192-4. PubMed ID: 9674916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.